Financial Constraints to Molecular Biomarker Testing

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.

Related Videos

April 14, 2015

CancerTREATMENT NGS+ in the Clinic

Description: Dr. Boccia describes cases in which he uses CancerTREATMENT NGS+ in his clinical practice.

August 29, 2018

Accurate and Reproducible Measurement of PD-1/PD-L1

Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.